Cyclopharm Locks in 11-Site US Hospital Network Deal Worth Recurring Revenue
Cyclopharm locks in 11-site US hospital network deal
Cyclopharm Limited (ASX: CYC) has secured a multi-site agreement with the University of Pennsylvania Health System (UPHS), covering 11 clinical locations across Pennsylvania and New Jersey. The agreement includes two immediate installations at flagship facilities, the Hospital of the University of Pennsylvania and the Perelman Center for Advanced Medicine, with contracted rollout across a further nine sites over time. The agreement has an initial three-year term and includes potential for expansion beyond the contracted locations.
UPHS is ranked as a top 20 hospital in the United States and the leading hospital in Pennsylvania, according to US News and World Report 2025-2026. The hospital system operates as a premier academic health network with national influence in clinical research and advanced imaging. For Cyclopharm, securing an agreement of this scale represents a major lighthouse account in the Philadelphia market, providing a strategic foothold for broader expansion across the mid-Atlantic and Northeast regions.
Multi-site agreements are the commercial model that creates operating leverage. Rather than negotiating individual hospital contracts site by site, one agreement unlocks recurring revenue across multiple facilities within an integrated network. This structure significantly reduces sales friction and accelerates deployment timelines.
When big ASX news breaks, our subscribers know first
Why integrated delivery network deals matter for medical device companies
An Integrated Delivery Network (IDN) is a group of hospitals and clinics operating under unified management and purchasing. These networks standardise procurement decisions across their entire system, meaning a single commercial agreement can provide access to multiple clinical sites simultaneously.
For medical device companies like Cyclopharm, IDN agreements deliver three key advantages:
-
Reduced sales friction: One negotiation replaces the need for separate contracts at each location, streamlining administrative processes and reducing cost-to-serve.
-
Faster rollout: Once an agreement is in place, deployment across network sites can proceed on a coordinated timeline rather than individual hospital approval cycles.
-
Built-in expansion pathways: IDN contracts often include provisions for additional sites beyond the initial scope, creating organic growth opportunities within an established commercial relationship.
Cyclopharm’s stated strategy centres on moving from initial installations to system-wide adoption within large US healthcare networks. The UPHS deal represents execution of this playbook, with 11 contracted sites providing immediate regional density and a framework for further expansion.
Revenue mechanics of the Technegas model
Cyclopharm’s commercial model generates revenue through three distinct streams. Each Technegas® installation creates an ongoing revenue relationship rather than a one-off equipment sale.
| Revenue Stream | Description | Timing |
|---|---|---|
| Installation | Upfront equipment placement | One-time |
| Annual Support | Service and maintenance fees | Recurring |
| Consumables | Per-patient procedure fees | Recurring |
The two immediate installations at high patient volume centres provide near-term revenue initiation. The Hospital of the University of Pennsylvania and the Perelman Center for Advanced Medicine are flagship facilities within the UPHS network, indicating substantial procedural volumes that will drive consumables usage.
Each installation generates ongoing consumables revenue on a per-patient procedure basis, alongside annual service and support fees. This recurring profile creates predictable revenue streams that compound as network utilisation increases across the 11 contracted locations.
Strategic positioning in the US market
Academic health systems function as lighthouse accounts in medical device markets. UPHS serves as a key opinion leader institution, influencing clinical adoption standards across both affiliated networks and independent healthcare systems that look to leading academic centres for practice guidance.
The Philadelphia market entry provides Cyclopharm with a prestigious reference site that carries national weight. As a top-ranked academic health system, UPHS’s clinical decisions are closely watched by other institutions evaluating new technologies. A strong performance record across the 11-site network creates commercial leverage for negotiations with other IDNs.
The geographic positioning also matters strategically. Philadelphia sits at the centre of the mid-Atlantic corridor, a region with high hospital density and significant patient volumes. Establishing presence in this market provides a foundation for expansion across Pennsylvania, New Jersey, and neighbouring states in the Northeast.
The academic research dimension adds further strategic value. UPHS’s involvement in clinical research and advanced imaging positions it to drive adoption of Beyond PE applications, which include:
- COPD (chronic obstructive pulmonary disease)
- Asthma
- Interstitial lung disease
- Oncology-related pulmonary assessment (including lobectomies in lung cancer and lung volume reduction surgery)
Historically used primarily for pulmonary embolism (PE) diagnosis, Technegas® is being deployed across these additional disease states as complementary imaging technology and analytical software advance. Increased clinical utilisation across multiple UPHS sites is expected to accelerate adoption of these Beyond PE applications, expanding the addressable patient population per installation.
CEO commentary on the milestone
James McBrayer, Managing Director and CEO
“Securing an 11-site agreement with the University of Pennsylvania Health System represents a significant milestone in our US expansion. Multi-site agreements of this nature are central to driving scalable, recurring revenue growth and improving operating leverage as utilisation increases. This is a high-quality academic health system with national influence across both clinical practice and research. Establishing Technegas® across multiple UPHS locations provides immediate scale and positions us for deeper institutional penetration over time.”
McBrayer’s commentary emphasises the scalability aspect of the agreement. As utilisation increases across the network, operating leverage improves because the fixed costs of the commercial relationship are spread across growing procedure volumes. This dynamic is central to the investment thesis for medical device companies pursuing the IDN strategy.
The next major ASX story will hit our subscribers first
What comes next for Cyclopharm’s US rollout
The UPHS agreement includes potential for expansion beyond the contracted 11 locations at additional sites affiliated with the health system. This provides a defined pathway for organic growth within an established commercial relationship, avoiding the need to initiate new negotiations for each additional site.
The broader US strategy, as stated by Cyclopharm, focuses on establishing leading reference sites, building regional density, and expanding across large integrated delivery networks. The UPHS deal validates execution against all three of these objectives. The two immediate installations at flagship facilities establish the reference sites, the 11-site contract creates regional density in the mid-Atlantic corridor, and the IDN structure demonstrates successful penetration of large healthcare networks.
Commercial momentum is building in a manner consistent with the company’s stated playbook. The multi-site nature of this agreement represents progression from initial installations to system-wide adoption, the exact transition Cyclopharm has identified as central to its commercial model.
Investors should watch for similar IDN announcements as validation of the model’s repeatability. If Cyclopharm can replicate this structure with other major academic health systems or large hospital networks, it would indicate that the commercial approach is scalable beyond individual lighthouse wins. The three-year initial contract term provides a defined timeframe for demonstrating clinical performance and utilisation growth that could support renewal and expansion when the term concludes.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to get market-moving announcements delivered straight to your inbox the moment they drop.